NBIX vs VSTD · P/E 45, rev $2.36B vs rev $12.8M
Neurocrine Biosciences Inc (NBIX) versus Vestand Inc. (VSTD) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Vestand Inc. (VSTD) is a restaurants company listed on NASDAQ.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported VSTD revenue for 2024-12-31 was $12.8M. Net income was -$2.7M. Revenue was up 39.3% from 2023-12-31 to 2024-12-31. VSTD currently screens at market cap $4.5M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. VSTD currently screens at market cap $4.5M.
Not investment advice. Open the NBIX and VSTD stock pages for the full models.
Not investment advice.